View published articles from peer-reviewed journals
2022
True
High Utilization of CYP2D6 Substrate Prescriptions Among Long-Term Care Residents With Overactive Bladder
Ann Longterm Care 2022
True
CYP2D6 Substrate Dispensing Among Patients Dispensed Mirabegron: An Administrative Claims Analysis
Drugs Real World Outcomes 2022
False
Efficacy and Safety of Vibegron for the Treatment of Overactive Bladder in Women: A Subgroup Analysis From the Double-Blind, Randomized, Controlled EMPOWUR Trial
Urogynecology 2022
True
Selectivity and Maximum Response of Vibegron and Mirabegron for β3-Adrenergic Receptors
Curr Ther Res. 2022
True
Impact of Urinary Incontinence Related to Overactive Bladder on Long-Term Care Residents and Facilities: A Perspective from Directors of Nursing
J Gerontol Nurs. 2022
True
Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA.
PharmacoEconomics 40, 979–988 (2022).
True
Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States.
Journal of Medical Economics 2022, 25:1, 1092-1100
True
Long-Term Efficacy and Safety of Vibegron Versus Mirabegron and Anticholinergics for Overactive Bladder: A Systematic Review and Network Meta-Analysis
Drugs Context 2022
True
Pharmacokinetics and Safety of Vibegron 75 mg Administered as an Intact or Crushed Tablet in Healthy Adults
Clin Pharmacol Drug Dev. 2022
False
Vibegron for the treatment of patients with dry and wet overactive bladder: a subgroup analysis from the EMPOWUR trial.
Int J Clin Pract. 2022;2022:(9 pages). doi:10.1155/2022/6475014
False
An evaluation of the efficacy and safety of vibegron in the treatment of overactive bladder.
Ther Clin Risk Manag. 2022;18:171-182. doi:10.2147/TCRM.S310371
False
Interpretation of the meaningfulness of symptom reduction with vibegron in patients with overactive bladder: analyses from EMPOWUR.
Adv Ther. 2022;39:959-970. doi:10.1007/s12325-021-01972-8
False
Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial.
Blood Press Monit. 2022;27(2):128-134. doi:10.1097/MBP.0000000000000572
2021
True
Efficacy of vibegron and mirabegron for overactive bladder: A systematic literature review and indirect treatment comparison.
Kennelly et al. Adv Ther. 2021
True
Overactive Bladder Prescribing Considerations: The Role of Polypharmacy, Anticholinergic Burden, and CYP2D6 Drug-Drug Interactions
Clin Drug Investig. 2021
True
Overactive Bladder Health Care Burden in the US Long-Term Care Setting: A Retrospective Cohort Study
J Clin Pathways. 2021
True
Gene Therapy for Overactive Bladder: A Review of BK-Channel α-Subunit Gene Transfer
Ther Clin Risk Manag. 2021
False
Vibegron improves quality-of-life measures in patients with overactive bladder: patient-reported outcomes from the EMPOWUR study.
Int J Clin Pract. 2021;75(5):e13937. doi:10.1111/ijcp.13937
False
Efficacy and safety of once-daily vibegron for treatment of overactive bladder in patients aged ≥65 and ≥75 years: subpopulation analysis from the EMPOWUR randomized, international, phase Ill study.
Drugs Aging. 2021;38:137-146. doi:10.1007/s40266-020-00829-z
2020
True
Increased risk of incident dementia following use of anticholinergic agents: A systematic literature review and meta‐analysis
Neurourol Urodyn. 2020
True
Optimizing Nonsurgical Treatments of Overactive Bladder in the United States
Urology 2020
True
Evaluating the safety and potential activity of URO‐902 (hMaxi‐K) gene transfer by intravesical instillation or direct injection into the bladder wall in female participants with idiopathic (non‐neurogenic) overactive bladder syndrome and detrusor...
Neurourol Urodyn. 2020
False
Once-daily vibegron 75 mg for overactive bladder: long-term safety and efficacy from a double-blind extension study of the international phase 3 trial (EMPOWUR).
J Urol. Published online December 28, 2020. doi:10.1097/JU.0000000000001574
False
Vibegron 50 mg is the optimal algorithm in the pharmacologic management of overactive bladder: outcomes from a systematic review and meta-analysis.
Int Urol Nephrol. 2020;52(12):2215-2221. doi:10.1007/s11255-020-02536-5
False
Evaluating vibegron for the treatment of overactive bladder.
Expert Opin Pharmacother. 2020 Sep 29:1-9. [Epub ahead of print] doi:10.1080/14656566.2020.1809652
False
International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR.
J Urol. 2020;204(2):316-324. doi:10.1097/JU.0000000000000807
False
Effects of vibegron, a novel β3-adrenoceptor agonist, and its combination with imidafenacin or silodosin in a rat with partial bladder outlet obstruction.
Eur J Pharmacol. Published online July 5, 2020. doi:10.1016/j.ejphar.2020.173096
False
The efficacy and safety of vibegron in treating overactive bladder: a systematic review and pooled analysis of randomized controlled trials.
Neurourol Urodyn. 2020;39(5):1255-1263. doi:10.1002/nau.24387
False
Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study.
BJU Int. 2020;125(5):709-717. doi:10.1111/bju.15020
2019
False
Efficacy of novel β3-adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: a post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study.
Int J Urol. 2019;26(3):369-375. doi:10.1111/iju.13877
False
Effects of the combination of vibegron and imidafenacin on bladder function in urethane-anesthetized rats.
Eur J Pharmacol. Published online December 1, 2019. doi:10.1016/j.ejphar.2019.172727
False
Vibegron (RVT-901/MK-4618/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial.
Eur Urol. 2019;75(2):274-282. doi:10.1016/j.eururo.2018.10.006
2018
False
Vibegron: first global approval.
Drugs. 2018;78(17):1835-1839. doi:10.1007/s40265-018-1006-3
False
Synthesis of vibegron enabled by a ketoreductase rationally designed for high pH dynamic kinetic reduction.
Angew Chem Int Ed Engl. 2018;57(23):6863-6867. doi:10.1002/anie.201802791
False
Vibegron, a novel potent and selective β3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study.
Eur Urol. 2018;73(5):783-790. doi:10.1016/j.eururo.2017.12.022
False
Long‐term safety and efficacy of the novel β3‐adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: a phase III prospective study.
Int J Urol. 2018;25(7):668-675. doi:10.1111/iju.13596
2017
False
2D-QSAR and 3D-QSAR/CoMSIA studies on a series of (R)-2-((2-(1H-indol-2-yl)ethyl)amino)-1-phenylethan-1-ol with human β3-adrenergic activity.
Molecules. 2017;22(3):404. doi:10.3390/molecules2203040
False
Pharmacological characterization of a novel beta 3 adrenergic agonist, vibegron: evaluation of antimuscarinic receptor selectivity for combination therapy for overactive bladder.
J Pharmacol Exp Ther. 2017;360(2):346-355. doi:10.1124/jpet.116.237313
2016
False
Discovery of vibegron: a potent and selective β3-adrenergic receptor agonist for the treatment of overactive bladder.
J Med Chem. 2016;59(2):609-623. doi:10.1021/acs.jmedchem.5b01372
Search results (0 results)
Try adjusting your keyword(s). Separate each keyword with a comma. You can also submit a question, or contact Urovant Medical Affairs at 833-UROVANT.
Documents obtained from search may contain information that is not included in the approved product labeling. Urovant does not endorse the use of its products in a manner not consistent with the approved label. Please refer to the full product labeling for complete prescribing information and important safety information.
